Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0206)
Drug Name
Betaxolol
Synonyms
Betaxolol [INN:BAN]; Betaxololum; Betaxololum [INN-Latin]; Betoptic; Betoptic S; KERLEDEX; Kerlone; NWIUTZDMDHAVTP-UHFFFAOYSA-N; Q-200713; SL 75212; SL-75212; betaxolol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-; 63659-18-7; CHEBI:3082; DSSTox_CID_2674; DSSTox_GSID_22674; DSSTox_RID_76685; NCGC00015159-06; ALO-1401-02
Indication Essential hypertension [ICD11: BA00] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 307.4 Topological Polar Surface Area 50.7
Heavy Atom Count 22 Rotatable Bond Count 11
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
Cross-matching ID
PubChem CID
2369
PubChem SID
9067 ; 4422029 ; 7978782 ; 8151588 ; 11466410 ; 11467530 ; 11486220 ; 14776435 ; 26751960 ; 29221537 ; 46506041 ; 47285407 ; 47656606 ; 47953968 ; 48328568 ; 48403963 ; 48415634 ; 49698465 ; 50022975 ; 50104633 ; 50655308 ; 51091849 ; 57321285 ; 85208966 ; 85788861 ; 90341580 ; 92308843 ; 92719119 ; 92729932 ; 96099855 ; 103164936 ; 103936438 ; 104171116 ; 104300392 ; 124749530 ; 124879433 ; 124879434 ; 124879436 ; 125329917 ; 126621071 ; 126650548 ; 126670422 ; 128764229 ; 131322111 ; 134337617 ; 135004759 ; 135565733 ; 135649987 ; 135692415 ; 137111818
ChEBI ID
CHEBI:3082
CAS Number
63659-18-7
TTD Drug ID
D03ROX
Formula
C18H29NO3
Canonical SMILES
CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
InChI
1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
InChIKey
NWIUTZDMDHAVTP-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Betaxolol metabolite M1 DM001405 N. A. Oxidation - O-Dealkylation 1 [4]
Betaxolol metabolite M2 DM001407 N. A. Oxidation - Oxidation 1 [4]
Betaxolol metabolite M3 DM001409 N. A. Conjugation - N-Glucuronidation; O-Glucuronidation 1 [4]
Betaxolol metabolite M4 DM001410 N. A. Conjugation - N-Glucuronidation; O-Glucuronidation 1 [4]
Betaxolol metabolite M5 DM001404 N. A. Oxidation - N-Dealkylation 1 [4]
Betaxolol metabolite M6 DM001408 N. A. Conjugation - N-Glucuronidation; O-Glucuronidation 1 [4]
Betaxolol metabolite M8 DM001402 N. A. Conjugation - N-Methylation; O-Methylation 1 [4]
Betaxolol metabolite M9 DM001406 N. A. Conjugation - O-Acetylation 1 [4]
Betaxolol metabolite M7 DM001403 N. A. Conjugation - N-Methylation; O-Methylation 2 [4]
Betaxolol metabolite M7 DM001403 N. A. Oxidation - Methylation; N-Dealkylation 2 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000354 Betaxolol Betaxolol metabolite M8 Conjugation - N-Methylation; O-Methylation Unclear [4]
MR000355 Betaxolol Betaxolol metabolite M5 Oxidation - N-Dealkylation Unclear [4]
MR000356 Betaxolol Betaxolol metabolite M1 Oxidation - O-Dealkylation Unclear [4]
MR000357 Betaxolol Betaxolol metabolite M9 Conjugation - O-Acetylation Unclear [4]
MR000358 Betaxolol Betaxolol metabolite M2 Oxidation - Oxidation Unclear [4]
MR000359 Betaxolol Betaxolol metabolite M6 Conjugation - N-Glucuronidation; O-Glucuronidation Unclear [4]
MR000360 Betaxolol Betaxolol metabolite M3 Conjugation - N-Glucuronidation; O-Glucuronidation Unclear [4]
MR000361 Betaxolol Betaxolol metabolite M4 Conjugation - N-Glucuronidation; O-Glucuronidation Unclear [4]
MR000353 Betaxolol metabolite M5 Betaxolol metabolite M7 Conjugation - N-Methylation; O-Methylation Unclear [4]
MR000352 Betaxolol metabolite M8 Betaxolol metabolite M7 Oxidation - Methylation; N-Dealkylation Unclear [4]
⏷ Show the Full List of 10 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[3]
References
1 Betaxolol was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Drugs that may have potential CYP1A2 interactions.
3 Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43.
4 An in vitro approach to investigate ocular metabolism of a topical, selective 1-adrenergic blocking agent, betaxolol Xenobiotica. 2015 May;45(5):396-405. doi: 10.3109/00498254.2014.987191.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.